Incruse Ellipta (umeclidinium) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). The drug comes as a dry powder that you inhale. It’s typically used once per ...

Incruse Ellipta (umeclidinium) is a brand-name inhaler prescribed for chronic obstructive pulmonary disease (COPD) in adults. As with other drugs, Incruse Ellipta can cause side effects, such as ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription inhaler used to treat asthma or COPD in adults. This drug can interact with certain ...

Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose. Incruse Ellipta should be stored at room temperature between 68°-77° F (20°-25° C); excursions permitted from ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler prescribed for COPD and asthma. Trelegy Ellipta has interactions with some other drugs ...

Anoro Ellipta combines umeclidinium 62.5mcg, a long-acting muscarinic antagonist, and vilanterol 25mcg, a long-acting beta2-agonist (LABA). Umeclidinium exerts its effect through inhibition of M3 ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

Some people with asthma need to use multiple inhaled medicines each day to keep their symptoms under control. The approval of long-acting, combination inhalers that contain more than one medicine is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This is the eighth FDA clearance Propeller Health has received for its respiratory therapy platform. Propeller had previously earned the CE Mark in Europe and approval by Health Canada to sell the ...

The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of fluticasone furoate and vilanterol (FF/VI) (Revinty ...

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (lse/nyse:GSK) and Theravance, Inc. THRX +1.96% today announced that Anoro™ Ellipta® ...